1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

US FDA 2020 Budget Request Is Parting Gift From Commissioner Gottlieb

 
• By Michael McCaughan

The Trump Administration’s request to increase FDA funding by 12% is a reminder of the behind-the-scenes benefits brought to FDA by the outgoing commissioner. The proposed increase for FDA stands in stark contrast to what is otherwise an austerity budget for HHS agencies.

Budget 2020. The inscription on the missing element of the puzzle. Folded white puzzles elements and one red with word BUDGET 2020. 3D Illustration - Illustration

US FDA Commissioner Scott Gottlieb is giving his successor a very nice parting gift in the form of a large requested funding increase in the Trump Administration’s latest budget proposal.

President Trump’s fiscal 2020 budget request seeks a 12% increase in appropriated funding for the Food & Drug Administration in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

AI Will Bolster, Not Squelch, Patient Voice In Clinical Research, US FDA Says

 
• By Sue Sutter

Artificial intelligence tools used for clinical research should be developed with input from patients and focus on their needs and abilities, FDA experts said.

US FDA’s Top Cell and Gene Therapy Regulators Forced Out

 
• By Sarah Karlin-Smith

Office of Therapeutic Products Director Nicole Verdun and her deputy Rachael Anatol were escorted out of FDA headquarters on June 18. Disagreements over CAR-T regulation and Capricor’s DMD treatment may be to blame.

First Among Equals: US FDA CBER Director Prasad Gains Agency-Wide Authority

 
• By Bridget Silverman

As Chief Medical and Scientific Officer, Vinay Prasad will advise the FDA Commissioner on cross-cutting issues, provide strategic leadership and be a public face of the agency.

BIO Notebook: Policy Problems, ACIP’s Future, BI Is Popular, Makary On FDA-Industry Ties

 
• By Sarah Karlin-Smith and Mandy Jackson

Highlights from Day Two of the BIO International Convention include BIO officials raising concerns about Trump Administration policies, the future of ACIP, an interview with BI's head of global business development, and FDA Commissioner Martin Makary's view of the FDA-industry relationship.

More from Agency Leadership